Last reviewed · How we verify
HIF-PHI
At a glance
| Generic name | HIF-PHI |
|---|---|
| Sponsor | Second Xiangya Hospital of Central South University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- REDCURE Registry for Chronic Kidney Disease (CKD) Anemia
- A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI) (NA)
- Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients (PHASE4)
- Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients (PHASE1,PHASE2)
- Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients (PHASE1,PHASE2)
- Two Different Regiments of Pegmolesatide for Anemia in Patients With Chronic Kidney Disease Not Receiving Dialysis (PHASE4)
- Effect of Perioperative Roxadustat in Elective Lumbar Interbody Fusion Surgery. (PHASE3)
- 20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HIF-PHI CI brief — competitive landscape report
- HIF-PHI updates RSS · CI watch RSS
- Second Xiangya Hospital of Central South University portfolio CI